Interactions between Acidophilus and Azacitidine
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- Acidophilus (lactobacillus acidophilus)
- azacitidine
Drug interactions
Moderate drug interactions
Moderate:
lactobacillus acidophilus azaCITIDine
Applies to: Acidophilus (lactobacillus acidophilus) and azacitidine
Monitor
Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. Although probiotics are generally considered safe, with minimal to low pathogenicity, infections such as bacteremia and endocarditis with various strains commonly found in probiotics (e.g., lactobacilli, bifidobacteria, Bacillus subtilis) have been rarely reported, primarily in critically ill patients or patients with significant underlying medical conditions such as malignancy, organ transplantation, AIDS, valvular heart disease, diabetes mellitus, recent surgery, or compromised immune system. Lactobacillus bacteremia has also been reported following endoscopy. In addition, cases of lactobacillus pneumonia and liver abscess, as well as Saccharomyces fungemia, pneumonia, liver abscess, peritonitis and vaginitis, have been described in the medical literature.
Management
Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.
References (12)
- Salminen MK, Rautelin H, Tynkkynen S, et al. (2004) "Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG." Clin Infect Dis, 38, p. 62-9
- Salminen MK, Tynkkynen S, Rautelin H, et al. (2002) "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis, 35, p. 1155-60
- Rautio M, Jousimies-Somer H, Kauma H, et al. (1999) "Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG." Clin Infect Dis, 28, p. 1159-60
- Schlegel L, Lemerle S, Geslin P (1998) "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis, 17, p. 887-8
- Saxelin M, Chuang NH, Chassy B, et al. (1996) "Lactobacilli and bacteremia in southern Finland, 1989-1992" Clin Infect Dis, 22, p. 564-6
- Husni RN, Gordon SM, Washington JA, Longworth DL (1997) "Lactobacillus bacteremia and endocarditis: review of 45 cases." Clin Infect Dis, 25, p. 1048-55
- Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C (1998) "Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis." J Clin Microbiol, 36, p. 325-6
- Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM (1999) "Lactobacillus endocarditis caused by a probiotic organism." Clin Microbiol Infect, 5, p. 290-2
- Borriello SP, Hammes WP, Holzapfel W, et al. (2003) "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis, 36, p. 775-80
- Lolis N, Veldekis D, Moraitou H, et al. (2008) "Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin." Crit Care, 12, epub
- Boyle RJ, Robins-Browne RM, Tang ML (2006) "Probiotic use in clinical practice: what are the risks?" Am J Clin Nutr, 83, p. 1256-64
- Pruccoli G, Silvestro E, Napoleone CP, Aidala E, Garazzino S, Scolfaro C (2024) Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. https://www.researchgate.net/publication/333853508_Are_probiotics_safe_Bifidobacterium_bacteremia_in_a_child_with_severe_heart_failure
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Anemia, Liver Disease, Thrombocytopenia, Immunodeficiency, and Neutropenia.
Anemia
Moderate:
azacitidine
azaCITIDine has a moderate potential interaction with Anemia.
Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
Hepatic Tumor
Major:
azacitidine
azaCITIDine has a major potential interaction with Hepatic Tumor.
The use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.
Immunodeficiency
Moderate:
Acidophilus
The lactobacillus acidophilus in Acidophilus has a moderate potential interaction with Immunodeficiency.
Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.
Liver Disease
Moderate:
azacitidine
azaCITIDine has a moderate potential interaction with Liver Disease.
Azacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.
Neutropenia
Moderate:
azacitidine
azaCITIDine has a moderate potential interaction with Neutropenia.
Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
Renal Dysfunction
Moderate:
azacitidine
azaCITIDine has a moderate potential interaction with Renal Dysfunction.
Patients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.
Thrombocytopenia
Moderate:
azacitidine
azaCITIDine has a moderate potential interaction with Thrombocytopenia.
Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
Report options
More resources
Acidophilus
A total of 370 drugs are known to interact with Acidophilus.
- Acidophilus is in the following drug classes: antidiarrheals, probiotics.
- Acidophilus is used to treat the following conditions:
azacitidine
A total of 189 drugs are known to interact with azacitidine.
- Azacitidine is in the drug class miscellaneous antineoplastics.
- Azacitidine is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.